Posts Tagged ‘GlaxoSmithKline’

At any given time, a principal investigator (PI) can be working on one or more studies for a single sponsor company, or multiple studies for multiple sponsors. Likewise, each sponsor runs its clinical trials its own way, using its preferred technology and processes. And, often times, the technology and/or processes differ from study to study, […]

Happy May Day! Now that May is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in April – they’re ranked in order of popularity, with number one being the most viewed piece. My Colleagues […]

When discussing the impact the United States’ new administration may have on pharmaceutical companies, GlaxoSmithKline’s Andrew Witty may have said it best: “I’ve had 30 years in this industry, and there’s never been a dull year. And there’s never been a year where it hasn’t felt challenging and interesting. And I suspect the next 30 years won’t be […]

Life sciences is one of the most heavily regulated industries in the United States. It takes 10 to 15 years and an average of $2.6 billion for a drug to reach pharmacy shelves. Stringent regulations formed by the FDA are major factors for the lengthy timelines and high costs, sometimes preventing people from receiving potentially […]

In August of last year, I wrote a blog piece that discusses the possibility of GlaxoSmithKline (GSK) being one of the first pharmaceutical companies to use Apple’s ResearchKit. It appears that possibility has become reality. According to Bloomberg, the global pharma company will be leveraging a mobile app they created on ResearchKit to obtain information […]

  Back in April, I wrote the piece 5 Apps Leveraging Apple’s ResearchKit For Clinical Studies. What’s interesting, in retrospect, is that none of those apps were developed by pharmaceutical companies, but rather by academic medical centers and nonprofit organizations.